Edwards Lifesciences (NYSE:EW) will issue its quarterly earnings data after the market closes on Tuesday, April 23rd. Analysts expect the company to announce earnings of $1.23 per share for the quarter. Edwards Lifesciences has set its Q1 guidance at $1.15-1.25 EPS and its FY19 guidance at $5.05-5.30 EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.17. The company had revenue of $977.70 million for the quarter, compared to analysts’ expectations of $973.72 million. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. During the same period last year, the business posted $0.94 earnings per share. On average, analysts expect Edwards Lifesciences to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

EW stock opened at $177.26 on Friday. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $36.88 billion, a price-to-earnings ratio of 37.71, a P/E/G ratio of 2.46 and a beta of 0.91. Edwards Lifesciences has a 1 year low of $123.00 and a 1 year high of $197.86.

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 1,474 shares of the business’s stock in a transaction dated Thursday, February 21st. The shares were sold at an average price of $176.34, for a total value of $259,925.16. Following the sale, the vice president now directly owns 15,905 shares in the company, valued at $2,804,687.70. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $167.89, for a total transaction of $5,506,792.00. Following the completion of the sale, the chief executive officer now owns 67,126 shares in the company, valued at $11,269,784.14. The disclosure for this sale can be found here. Over the last quarter, insiders sold 114,328 shares of company stock worth $20,121,304. 1.63% of the stock is owned by company insiders.

EW has been the topic of a number of recent analyst reports. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $180.00 to $190.00 in a research note on Friday, January 18th. Citigroup lifted their price objective on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the company a “sell” rating in a research note on Wednesday, January 2nd. Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $180.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Barclays lifted their price objective on shares of Edwards Lifesciences from $150.00 to $160.00 and gave the company an “underweight” rating in a research note on Monday, March 25th. Finally, Deutsche Bank initiated coverage on shares of Edwards Lifesciences in a research note on Wednesday, January 2nd. They set a “hold” rating and a $164.00 price objective on the stock. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $182.29.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences (EW) Scheduled to Post Quarterly Earnings on Tuesday” was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/edwards-lifesciences-ew-scheduled-to-post-quarterly-earnings-on-tuesday/2977985.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: Bollinger Bands

Earnings History for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.